The Overnight Picture

U.S. equity futures pointed lower heading into Thursday's session, with the dominant weight coming not from any single earnings miss but from a macro reassessment that has been building across multiple sessions. Investors have been repricing the likelihood of a Federal Reserve rate increase before year-end — a shift that compresses valuations across the board and makes the current earnings season feel less like a tailwind than it otherwise might.

The concern is structural. The Federal Reserve sets the federal funds rate — the benchmark borrowing cost that ripples through mortgages, corporate debt, and equity discount rates. When markets begin pricing in rate hikes rather than cuts, the arithmetic of stock valuations tightens. That is the environment traders are navigating this morning.

Adding a geopolitical dimension, Goldman Sachs reversed its earlier forecast of a global oil glut, flagging renewed hostilities in the Persian Gulf as a credible threat to crude supply. The Strait of Hormuz — the narrow waterway through which a substantial share of the world's seaborne oil travels — had seen tanker traffic fall to near zero in the wake of fresh U.S.-Iran escalation. Goldman's warning matters because higher oil prices feed directly into inflation expectations, which in turn reinforces the case for tighter monetary policy. The feedback loop is precisely what markets are watching.

Theme One: The Fed's Shadow Over Equities

The rate-hike anxiety is the broadest and most consequential driver in today's session. No specific Fed statement or data release has been identified as the immediate trigger, but the concern reflects accumulated uncertainty about the inflation trajectory — particularly now that energy prices carry fresh upside risk from the Gulf.

Higher borrowing costs hurt equities through two channels simultaneously: they raise the cost of capital for companies, compressing margins, and they make fixed-income alternatives more attractive relative to stocks. Growth-oriented and long-duration assets — technology companies with valuations built on distant future earnings — tend to feel this most acutely. The sell-off arriving despite a generally constructive corporate earnings backdrop signals that the macro concern is carrying real weight in positioning decisions today.

Watch the bond market closely. If Treasury yields continue to climb, that will confirm the rate-hike narrative is gaining traction among fixed-income traders, not just equity investors.

Theme Two: AstraZeneca's $27 Billion Single-Session Wipeout

AstraZeneca (AZN) suffered one of the sharpest single-session market value destructions in recent pharmaceutical history after its heart disease drug Wainua — developed in partnership with Ionis Pharmaceuticals (IONS) — failed to outperform a placebo in a pivotal clinical trial.

Wainua was designed to treat ATTR-CM, a progressive cardiac condition caused by a protein called transthyretin accumulating in heart tissue. Pivotal trials — the large-scale, controlled studies that regulators require before approving a drug — represent the final and highest-stakes hurdle in drug development. A failure at this stage typically ends a drug's commercial prospects entirely, which is why the market reaction was immediate and severe: AZN lost approximately $27 billion in market capitalization.

For Ionis, which co-developed the therapy, the result is equally damaging to its cardiovascular pipeline. Both companies must now reassess their strategies in that therapeutic area. The episode is a reminder of the binary risk embedded in late-stage pharmaceutical development — even for large, well-resourced companies with diversified portfolios, a single pivotal trial can erase years of investment in a single session.

On the other side of the healthcare ledger, Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for approximately $10 billion. Crinetics shares surged roughly 99% on the news — a move consistent with the premium Vertex is paying to expand beyond its cystic fibrosis franchise into endocrine and metabolic diseases. The deal adds to a pattern of large pharmaceutical companies using acquisitions to replenish pipelines rather than relying solely on internal R&D.

Theme Three: AI Capital Deployment Reaches New Scale

While the macro and healthcare stories dominate sentiment today, the structural story of the session is the accelerating pace of AI infrastructure investment — and the increasingly creative financing mechanisms being deployed to fund it.

Apple (AAPL) extended its chip supply agreement with Broadcom (AVGO) through 2031 in a deal expected to exceed $30 billion. The commitment reinforces Broadcom's position as a critical supplier of custom silicon — chips designed specifically for Apple's workloads — and signals that the largest technology companies are locking in supply relationships years in advance.

Apollo Global Management is bringing a $35 billion private credit financing package to market, structured for Broadcom and AI startup Anthropic. Private credit — debt arranged outside traditional bank and public bond market channels — has grown rapidly as an asset class, and a deal of this scale signals that institutional investors are prepared to commit very large sums to AI infrastructure at terms unavailable in public markets. The transaction illustrates how the AI capital cycle is now flowing through alternative finance, not just equity markets.

AMD (AMD) separately announced plans to deploy six gigawatts of GPU capacity for Meta under a new partnership. The scale of that commitment — six gigawatts of compute — underscores the depth of hyperscaler demand for non-Nvidia processing power and suggests AMD is making meaningful inroads into a market long dominated by NVDA.

Taken together, these three deals show how AI capital spending is now moving simultaneously through chip supply agreements, private debt markets, and GPU deployment contracts — a multi-layer buildout that is reshaping the technology supply chain from silicon to software.

The Calendar

SpaceX's addition to the Nasdaq-100 is the structural market event to track today. Index inclusion triggers automatic buying by passive funds — investment vehicles that replicate an index rather than select individual stocks — and the estimated forced demand stands at approximately $4.3 billion. Funds tracking the Nasdaq-100, including the widely held QQQ ETF, must purchase SPCX shares in proportion to its index weight regardless of their own view on the company's valuation. SpaceX's unusual status as a non-traditionally listed company makes this inclusion a test case for how passive vehicles handle non-standard securities.

No major scheduled Federal Reserve speakers or economic data releases have been confirmed in the source material for today's session, but any commentary touching on the rate outlook will carry outsized significance given the current market anxiety.

Watch List

Treasury yields deserve close attention throughout the session. A continued move higher in the 10-year would confirm that bond markets are pricing in the same rate-hike concern driving equity weakness — and would likely deepen the sell-off in rate-sensitive sectors.

Crude oil is the second critical monitor. Goldman Sachs's reversal on the supply outlook, combined with near-zero tanker traffic through Hormuz, creates a setup where any further escalation in the Persian Gulf could push energy prices sharply higher. That in turn feeds inflation expectations and complicates the Fed's path — the macro feedback loop that is already weighing on equities.

In healthcare, watch for any management response from AstraZeneca or Ionis regarding pipeline strategy following the Wainua failure. How each company frames its cardiovascular ambitions going forward will shape investor confidence in their respective growth narratives.

Finally, track the mechanics of the SpaceX Nasdaq-100 rebalancing. The $4.3 billion in estimated passive inflows represents a concentrated demand event, and how SPCX trades around the rebalancing window will be instructive for anyone monitoring index-driven market structure dynamics.